Maresin 1 mitigates LPS‐induced acute lung injury in mice
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Acute lung injury (ALI) is a severe illness with a high rate of mortality.M aresin 1 (MaR1) was recently reported to regulate inflammatory responses. We used a LPS‐induced ALI model to determine whether MaR1 can mitigate lung injury. Experimental Approach: Male BALB/c mice were injected, intratracheally, with either LPS(3 mg·kg−1) or normal saline (1.5 mL·kg−1). After this, normal saline, a low dose of MaR1(0.1 ng per mouse) or a high dose of MaR1(1 ng per mouse) was given i.v. Lung injury was evaluated by detecting arterial blood gas, pathohistological examination, pulmonary oedema, inflammatory cell infiltration, inflammatory cytokines in the bronchoalveolar lavage fluid and neutrophil–platelet interactions. Key Results: The high dose of MaR1 significantly inhibited LPS‐induced ALI by restoring oxygenation, attenuating pulmonary oedema and mitigating pathohistological changes. A combination of elisa and immunohistochemistry showed that high‐dose MaR1 attenuated LPS‐induced increases in pro‐inflammatory cytokines (TNF‐α,IL‐1β and IL‐6), chemokines [keratinocyte chemokine, monocyte chemoattractant protein‐5, macrophage inflammatory protein (MIP)‐1α and MIP‐1γ], pulmonary myeloperoxidase activity and neutrophil infiltration in the lung tissues. Consistent with these observations, flow cytometry and Western blotting indicated that MaR1 down‐regulated LPS‐induced neutrophil adhesions and suppressed the expression of intercellular adhesion molecule (ICAM)‐1,P‐selection and CD 24. Conclusions and Implications: High‐dose MaR1 mitigated LPS‐induced lung injury in mice by inhibiting neutrophil adhesions and decreasing the levels of pro‐inflammatory cytokines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
The acute respiratory distress syndrome
Matthay, M. A., Ware, L. B., & Zimmerman, G. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60331 · Cited by 1,706
Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., & Moussignac, R.-L. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020760 · Cited by 1,650
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
McGrath, J., Drummond, G., McLachlan, E., Kilkenny, C., & Wainwright, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00873.x · Cited by 1,592
Maresins: Novel macrophage mediators with potent antiinflammatory and proresolving actions
Serhan, C. N., Yang, R., Martinod, K., Kasuga, K., Pillai, P. S., Porter, T. F., Oh, S. F., & Spite, M. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081880 · Cited by 908 · cited 4×
“These, in turn, are enzymatically transformed to generate resolvins, protectins and the most recently identified macrophage-derived pro-resolving mediators, denoted as the maresins (Serhan et al., 2009).”
BackgroundInfluentialDalli, J., Zhu, M., Vlasenko, N. A., Deng, B., Haeggström, J. Z., Petasis, N. A., & Serhan, C. N. (2013) · The FASEB Journal · doi:10.1096/fj.13-227728 · Cited by 283 · cited 2×
“Dalli et al. (2013) speculated that the novel 13S,14S-epoxy-maresin is converted by human macrophages to MaR1, which inhibits leukotriene A4 hydrolase and shifts macrophage phenotype.”
BackgroundAnti-inflammatory circuitry: Lipoxin, aspirin-triggered lipoxins and their receptor ALX
Chiang, N., Arita, M., & Serhan, C. N. (2005) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2005.05.003 · Cited by 239 · cited 1×
“Lipoxin A4, lipoxin B4 and aspirintriggered lipoxins (ATLs) are the first mediators biosynthesized from arachidonic acid (AA) (Chiang et al., 2005; Alessandri et al., 2013; for nomenclature see Alexander et al., 2013).”
Background
Cited by
Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs
Gabbs, M., Leng, S., Devassy, J. G., Monirujjaman, M., & Aukema, H. M. (2015) · Advances in Nutrition · doi:10.3945/an.114.007732 · Cited by 798
Lipid metabolism in critical illness
Green, P., Theilla, M., & Singer, P. (2016) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0000000000000253 · Cited by 76
Maresin 1 attenuates pro‐inflammatory activation induced by β‐amyloid and stimulates its uptake
Wang, Y., Leppert, A., Tan, S., van der Gaag, B., Li, N., Schultzberg, M., & Hjorth, E. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16098 · Cited by 33
Self-citation
Metadata
- Authors
- Gong, J., Wu, Z., Qi, H., Chen, L., Li, H., Li, B., Yao, C., Wang, Y., Wu, J., Yuan, S., Yao, S., & Shang, Y.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2014-06-25
- Volume
- 171
- Issue
- 14
- Pages
- 3539-3550
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1535815464
- Cited by
- 186
- References
- 8
- FWCI
- 29.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Maresin 1 mitigates LPS‐induced acute lung injury in mice. https://app.cochat.ai/papers/10.1111/bph.12714
- The paper
- Gong, J., Wu, Z., Qi, H., Chen, L., Li, H., Li, B., Yao, C., Wang, Y., Wu, J., Yuan, S., Yao, S., & Shang, Y. (2014). Maresin 1 mitigates LPS‐induced acute lung injury in mice. British Journal of Pharmacology. https://doi.org/10.1111/bph.12714
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.